The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...
The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...
The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...
The global health landscape faces challenges and innovations, with the European review of Alzheimer's drug Leqembi, Ebola ...
Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...
Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...
Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...
Seeking Alpha on MSN8h
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback